These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4896406)

  • 1. ["Androgenic shock" during treatment of prostate gland cancer].
    Religa Z
    Pol Przegl Chir; 1969; 41(4):Suppl 4a:534+. PubMed ID: 4896406
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prolactin and cancer of the prostate (III). Changes in plasma prolactin and testosterone after hormone treatment in prostatic cancer].
    Maganto Pavón E; Mateos Torres JA; Mayayo Dehesa T; Allona Almagro A; Boronat Tormo F; Escudero Barrilero A
    Arch Esp Urol; 1982; 35(4):222-33. PubMed ID: 7138091
    [No Abstract]   [Full Text] [Related]  

  • 3. [Local action of different steroids in the human testis].
    Pascale CA; Romano HM; Mancini R
    Rev Argent Urol Nefrol; 1968; 37(8):240-6. PubMed ID: 5737025
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.
    van der Poel HG
    Eur Urol; 2009 Jul; 56(1):103-4. PubMed ID: 19282103
    [No Abstract]   [Full Text] [Related]  

  • 5. Estrogens in the treatment of prostate cancer.
    Cox RL; Crawford ED
    J Urol; 1995 Dec; 154(6):1991-8. PubMed ID: 7500443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
    Boccardo F; Pace M
    In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of hormone-resistant prostate cancer with estramustine phosphate (Estracyt)].
    Stridsklev IC; Fosså SD; Kaalhus O
    Tidsskr Nor Laegeforen; 1984 Oct; 104(28):1977-80. PubMed ID: 6388019
    [No Abstract]   [Full Text] [Related]  

  • 8. Is there still place for estrogens in the treatment of advanced prostatic carcinoma?
    Steg A
    Prog Clin Biol Res; 1987; 243B():429-34. PubMed ID: 3309995
    [No Abstract]   [Full Text] [Related]  

  • 9. [Serum testosterone level in patients with advanced prostatic cancer during androgen suppressive treatment].
    Fosså SD; Høst H; Aakvaag A
    Tidsskr Nor Laegeforen; 1981 Oct; 101(28):1570-3. PubMed ID: 7339933
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of advanced prostate cancer.
    Lynch JH
    J Fam Pract; 1993 Nov; 37(5):488-94. PubMed ID: 7693859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of estrongens in treatment of cancer of the prostate. Pyknotic index and cytology of the prostate].
    Kurth KH; Skoluda D; Schmidt H
    J Urol Nephrol (Paris); 1974 Dec; 80(12 pt 2):453-7. PubMed ID: 4469319
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnostic significance of the changes in calcium metabolism after administration of sexual steroids in cancer of the breast and prostate.
    MOLINATTI GM; CAMANNI F; OLIVETTI M
    Minerva Med; 1958 Jun; 49(48):2389-401. PubMed ID: 13565676
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of testosterone in the pathogenesis of prostate cancer.
    Imamoto T; Suzuki H; Yano M; Kawamura K; Kamiya N; Araki K; Komiya A; Nihei N; Naya Y; Ichikawa T
    Int J Urol; 2008 Jun; 15(6):472-80. PubMed ID: 18430151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormonotherapy for prostate cancer].
    Oishi K; Yoshida O
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2300-5. PubMed ID: 8259842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 16. [A cytological study of urinary sediment as a method of evaluating the efficacy of hormone therapy of cancer of the prostate gland].
    Dunaevskiĭ IaL
    Urol Nefrol (Mosk); 1968; 33(3):28-33. PubMed ID: 5669797
    [No Abstract]   [Full Text] [Related]  

  • 17. Testosterone therapy in castrate-resistant prostate cancer: a possible new approach.
    Gardiner RA; Sweeney C; Tilley WD
    Eur Urol; 2009 Aug; 56(2):245-6. PubMed ID: 19409691
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
    Sciarra A
    Eur Urol; 2009 Feb; 55(2):320-1. PubMed ID: 18838210
    [No Abstract]   [Full Text] [Related]  

  • 20. Long lasting results of the hormonal treatment for prostate cancer.
    Ljunggren E
    Acta Urol Belg; 1972 Jan; 40(1):108-12. PubMed ID: 5040189
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.